Cullinan Therapeutics Engages in Key Investor Conversations
CAMBRIDGE, Mass. – August 2025 – Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical innovator committed to advancing targeted therapies, is set to participate in a series of important investor conferences. These occasions will provide a platform for Cullinan’s leadership to discuss their ongoing developments and future strategies in the rapidly evolving healthcare landscape.
Upcoming Conferences Featuring Cullinan Leadership
During these conferences, Nadim Ahmed, the Chief Executive Officer, alongside Jeffrey Jones, M.D., M.B.A., the Chief Medical Officer, will engage in discussions meant to inform investors about their innovations and strategic vision.
Cantor Global Healthcare Conference
One highlight includes their participation in a fireside chat at the Cantor Global Healthcare Conference 2025 scheduled for September 4, 2025, at 2:10 p.m. ET. This event will gather various leaders in the healthcare industry, offering insights into current trends and advancements.
Morgan Stanley Annual Global Healthcare Conference
Furthermore, the team will be present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, starting at 8:30 a.m. ET. This institution is renowned for its focus on innovative healthcare companies and provides an excellent opportunity for Cullinan to showcase its pioneering projects.
Accessing Webcasts and Presentations
For those interested in viewing these discussions, webcasts will be available under the Events and Presentations section of Cullinan’s investor relations website. By visiting their site, investors can stay updated and engage with the insights shared by the Cullinan leadership team.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) stands at the forefront of biopharmaceutical innovation. The company is focused on developing new standards of care, aiming to address significant unmet medical needs across various therapeutic areas including oncology and autoimmune diseases. Cullinan has strategically built a broad portfolio of clinical-stage assets designed either to inhibit critical pathways in diseases or leverage the immune system to destroy harmful cells.
With a robust understanding of oncology and immunology, Cullinan approaches its drug development with a unique lens. By meticulously selecting the right therapeutic targets and employing state-of-the-art modalities, the company is on a mission to bring groundbreaking therapies to market. Each step of their development process is guided by careful evaluation and commitment to revolutionizing care for patients.
Contact Information
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media Inquiries
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
Frequently Asked Questions
What is Cullinan Therapeutics?
Cullinan Therapeutics is a biopharmaceutical company focused on developing targeted therapies to improve patient care in diseases like cancer and autoimmune disorders.
What investor conferences is Cullinan participating in?
Cullinan is participating in the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference.
How can I access the webcasts of their presentations?
The webcasts will be available on Cullinan’s investor relations website, ensuring you can access valuable insights directly from their leadership.
Who are the key executives presenting at the conferences?
Nadim Ahmed, the CEO, and Dr. Jeffrey Jones, the CMO, will be the primary speakers discussing Cullinan's strategic direction and innovations.
What are the main therapeutic areas Cullinan focuses on?
Cullinan is primarily focused on oncology and autoimmune diseases, developing therapies that can potentially change the standard of care for these conditions.
